{
  "id": 19172926,
  "title": "Tonix Q3 2026 slides: TONMYA sales up 37%, shares fall on loss",
  "url": "https://urgent.news/2026/11/09/tonix-q3-2026-slides-tonmya-sales-up-37-shares-fall-on-loss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T15:31:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/tonix-q3-2026-slides-tonmya-sales-up-37-shares-fall-on-loss-93CH-5012772"
  },
  "original_language": "en",
  "account": "Tonix Pharmaceuticals (NASDAQ:TNXP) reported its third quarter 2026 financial results on November 9, showcasing strong sales for its fibromyalgia treatment TONMYA while navigating higher expenses and a wider-than-expected loss. The company's revenue increased to $17.2 million, with TONMYA driving approximately $15 million in sales, marking a 37% quarter-over-quarter growth from the previous quarter. In addition to TONMYA, Zembrace SymTouch and TOSYMRA contributed $2.2 million to the total net revenue. Despite the growth in TONMYA sales, the company reported a loss of $2.89 per share, exceeding analysts' estimate of a $2.43 loss by 18.93%. The loss was primarily due to increased R&D expenses, which rose 177% year-over-year to $25.8 million, and higher SG&A expenses, which climbed 77% to $45.6 million. Although Tonix now has coverage for 53% of U.S. covered lives, representing 166 million people, the company's cash runway extends only into early third quarter 2027, raising concerns about its near-term financing needs.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}